Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Sacramento › NPI 1619913449
Lab

Unilab Corporation

Unilab Corporation was paid $141.24M by Medicaid between Jan 2018 and Dec 2024, across 551 billing codes. Its largest line is 87591, Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe — 7.8% of everything it billed.

33Billing provider infoUNILAB CORPORATION
SACRAMENTO, CA 95834
33aNPI1619913449assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$141.24M
24GClaims29,528,771
24DCodes billed551
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#8 of 561
Median peer was paid$222K
This provider vs. median636×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M$3.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20183,913,822$21.87M
20193,865,272$19.21M
20203,917,934$19.15M
20214,403,751$23.13M
20224,203,980$18.65M
20234,973,188$21.58M
2024incomplete4,250,824$17.64M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 7.8% 933,371 880,387 $10.97M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 7.7% 931,734 879,124 $10.94M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 4.7% 88,658 81,830 $6.58M
86480 4.5% 330,370 318,992 $6.38M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 4.3% 46,033 45,638 $6.04M
84443 Thyroid stimulating hormone (TSH) 3.6% 1,177,034 1,140,950 $5.08M
80053 Comprehensive metabolic panel 3.3% 2,000,273 1,872,698 $4.67M
80081 3.3% 128,600 120,148 $4.60M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3.2% 303,497 272,143 $4.57M
80061 Lipid panel 3.1% 1,745,769 1,707,704 $4.41M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 2.8% 730,232 714,314 $3.93M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 2.6% 559,642 544,172 $3.68M
539 more codes
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 2.5% 281,671 $3.48M
83036 Hemoglobin; glycosylated (A1C) 2.2% 1,568,498 $3.07M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.1% 1,668,284 $2.97M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 2.0% 264,423 $2.85M
81513 1.8% 58,942 $2.53M
87799 1.8% 199,893 $2.49M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.6% 221,727 $2.23M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.3% 149,811 $1.88M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 1.3% 150,486 $1.83M
86803 1.2% 473,581 $1.75M
86592 1.2% 796,202 $1.64M
86003 1.0% 52,334 $1.46M
83013 <1% 83,253 $1.18M
87086 Culture, bacterial; quantitative colony count, urine <1% 505,338 $1.16M
81329 <1% 17,998 $1.11M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 2,375 $1.01M
80074 <1% 82,406 $930K
87512 <1% 78,129 $859K
85027 <1% 559,713 $804K
84439 <1% 407,251 $801K
87088 <1% 387,450 $771K
87340 <1% 280,824 $760K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 22,913 $719K
82728 <1% 280,201 $717K
83655 <1% 208,451 $701K
87209 <1% 59,263 $694K
87536 <1% 33,916 $632K
86704 <1% 187,600 $582K
87522 Neg quan hep c or qual rna <1% 50,408 $550K
82607 <1% 260,485 $525K
83970 <1% 69,865 $523K
86708 <1% 174,504 $522K
84403 <1% 90,143 $520K
87902 <1% 8,659 $510K
82652 <1% 68,645 $504K
82746 <1% 182,812 $501K
86235 <1% 30,046 $491K
88142 <1% 55,820 $465K
86787 <1% 99,018 $449K
82570 <1% 468,895 $445K
84153 <1% 125,574 $436K
86706 <1% 130,416 $428K
82274 <1% 172,232 $411K
84702 <1% 88,975 $404K
82043 <1% 386,209 $381K
87177 <1% 59,254 $358K
81001 <1% 598,538 $352K
87255 <1% 18,101 $344K
83550 <1% 240,787 $343K
86696 <1% 51,173 $342K
83540 <1% 282,951 $335K
82951 <1% 67,535 $330K
80048 Basic metabolic panel (calcium, ionized) <1% 216,904 $317K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 5,829 $296K
81162 <1% 161 $290K
87186 <1% 120,818 $290K
87081 <1% 128,369 $288K
86038 <1% 110,074 $278K
86317 <1% 112,474 $268K
82670 <1% 40,616 $261K
86682 <1% 28,349 $257K
83001 <1% 64,635 $255K
86762 <1% 52,874 $248K
87077 <1% 107,800 $239K
83880 <1% 33,229 $227K
86695 <1% 49,092 $226K
84146 <1% 50,984 $220K
84402 <1% 34,179 $197K
83002 <1% 49,981 $196K
87070 <1% 84,622 $195K
86780 <1% 45,194 $194K
80197 <1% 43,051 $190K
86360 <1% 22,482 $189K
84445 <1% 13,305 $178K
84481 <1% 64,664 $177K
86140 <1% 183,667 $173K
86376 <1% 49,744 $171K
83735 <1% 108,784 $170K
82105 <1% 34,492 $167K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 1,369 $164K
87901 <1% 2,546 $164K
82785 <1% 45,616 $161K
87480 <1% 29,632 $158K
87510 <1% 29,635 $158K
87660 <1% 29,460 $154K
88185 <1% 1,288 $153K
87517 <1% 26,889 $146K
88141 <1% 41,783 $145K
86160 <1% 28,400 $136K
82950 <1% 81,308 $136K
83021 <1% 25,426 $135K
84425 <1% 30,264 $134K
82627 <1% 24,915 $133K
85610 <1% 152,324 $127K
86769 <1% 3,451 $126K
86147 <1% 19,834 $122K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 8,086 $120K
85652 <1% 220,877 $118K
86359 <1% 17,350 $118K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 3,338 $113K
80076 <1% 85,250 $112K
85730 <1% 75,495 $111K
84480 <1% 37,104 $111K
86146 <1% 17,856 $111K
82784 <1% 62,460 $109K
86008 <1% 5,196 $105K
86765 <1% 30,708 $105K
83020 <1% 31,352 $104K
86800 <1% 33,452 $104K
82947 <1% 87,386 $104K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 4,867 $102K
87497 <1% 8,239 $101K
86735 <1% 28,532 $101K
84550 <1% 131,242 $100K
83921 <1% 28,174 $94K
83014 <1% 54,140 $90K
83498 <1% 12,711 $86K
86431 <1% 78,493 $86K
86225 <1% 30,381 $85K
83516 <1% 40,663 $85K
87900 <1% 2,532 $83K
84270 <1% 16,468 $83K
82977 <1% 36,527 $82K
81596 <1% 10,128 $82K
83525 <1% 33,423 $81K
86200 <1% 46,600 $81K
80055 <1% 4,553 $79K
83993 <1% 14,264 $78K
84154 <1% 21,444 $78K
84436 <1% 70,069 $78K
84681 <1% 10,213 $77K
84460 <1% 93,653 $77K
80164 <1% 19,820 $77K
83690 <1% 52,244 $76K
87147 <1% 55,938 $76K
82378 <1% 33,222 $72K
83520 <1% 37,610 $70K
86709 <1% 57,033 $69K
86593 <1% 34,629 $68K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 3,856 $67K
86039 <1% 28,871 $67K
84144 <1% 15,685 $67K
84100 <1% 67,426 $66K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 534 $64K
84450 <1% 69,692 $64K
82330 <1% 22,885 $63K
80069 <1% 57,478 $62K
84156 <1% 87,206 $61K
82248 <1% 59,697 $58K
86364 <1% 18,463 $58K
87338 <1% 32,505 $56K
80159 <1% 7,534 $56K
83615 <1% 54,459 $55K
82533 <1% 16,120 $54K
84466 <1% 17,503 $54K
86300 <1% 16,718 $54K
82550 <1% 48,605 $53K
87481 <1% 7,782 $53K
82172 <1% 10,238 $53K
87045 <1% 23,824 $50K
86361 <1% 12,509 $50K
88230 <1% 1,563 $49K
87427 <1% 22,537 $49K
86850 <1% 45,498 $49K
82024 <1% 6,304 $48K
81243 <1% 3,750 $48K
87625 <1% 9,179 $47K
86665 <1% 8,379 $47K
86812 <1% 7,643 $46K
86334 <1% 21,857 $45K
88262 <1% 1,414 $45K
87999 <1% 605 $44K
87075 <1% 16,505 $43K
82542 <1% 7,336 $42K
86255 <1% 17,856 $42K
84207 <1% 5,784 $40K
84305 <1% 7,907 $40K
84590 <1% 15,093 $40K
82565 <1% 46,278 $39K
81257 <1% 1,955 $39K
84165 <1% 17,879 $37K
82150 <1% 27,580 $36K
82465 <1% 24,614 $36K
86162 <1% 3,734 $35K
82107 <1% 2,471 $35K
85045 <1% 32,759 $34K
82088 <1% 3,660 $34K
81401 <1% 353 $33K
84479 <1% 36,403 $33K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 2,441 $33K
86901 <1% 34,494 $33K
83090 <1% 9,272 $32K
86304 <1% 12,041 $32K
82247 <1% 26,961 $32K
87329 <1% 13,117 $32K
88112 <1% 2,933 $31K
86870 <1% 4,639 $31K
86141 <1% 14,771 $30K
87535 <1% 2,548 $30K
84703 <1% 17,866 $30K
85246 <1% 6,106 $30K
86301 <1% 9,281 $29K
85007 <1% 30,978 $29K
87449 <1% 15,137 $29K
80178 <1% 15,083 $29K
86664 <1% 6,913 $29K
86900 <1% 32,044 $28K
82140 <1% 7,611 $28K
86705 <1% 11,203 $27K
82952 <1% 18,640 $27K
87529 <1% 3,815 $27K
85018 <1% 67,437 $26K
85060 <1% 10,372 $26K
81206 <1% 795 $26K
85245 <1% 5,425 $25K
83704 <1% 5,098 $25K
86635 <1% 4,962 $25K
82672 <1% 6,009 $25K
81003 <1% 56,280 $23K
80177 <1% 7,767 $22K
84597 <1% 7,187 $22K
88189 <1% 1,050 $22K
83883 <1% 7,484 $22K
85240 <1% 5,732 $21K
85247 <1% 4,400 $21K
87662 <1% 350 $21K
87906 <1% 771 $21K
82530 <1% 3,304 $20K
85613 <1% 8,994 $20K
87205 <1% 19,250 $20K
84244 <1% 3,792 $20K
84432 <1% 7,884 $20K
82610 <1% 3,153 $20K
84478 <1% 17,020 $19K
87493 <1% 3,095 $19K
87631 <1% 552 $19K
84630 <1% 8,708 $19K
83521 <1% 4,541 $19K
85014 <1% 34,726 $19K
86382 <1% 1,016 $18K
86618 <1% 3,941 $18K
86355 <1% 12,300 $18K
86021 <1% 5,740 $18K
81381 <1% 433 $17K
86341 <1% 5,488 $17K
80050 General health panel <1% 166,022 $17K
81025 <1% 18,290 $17K
84446 <1% 6,697 $16K
83721 <1% 9,590 $16K
82239 <1% 2,335 $15K
88184 <1% 1,267 $15K
83695 <1% 9,202 $15K
83010 <1% 5,614 $15K
82103 <1% 4,994 $15K
86702 <1% 2,672 $15K
86381 <1% 3,869 $15K
87324 <1% 7,640 $15K
82040 <1% 21,371 $14K
82310 <1% 19,222 $14K
82390 <1% 6,857 $14K
87350 <1% 7,517 $14K
81269 <1% 85 $14K
82157 <1% 1,985 $13K
86015 <1% 5,075 $13K
86337 <1% 2,724 $13K
82525 <1% 5,340 $13K
82626 <1% 3,097 $13K
84134 <1% 3,832 $13K
84166 <1% 3,683 $12K
84520 <1% 20,640 $12K
84075 <1% 18,439 $12K
86701 <1% 2,921 $12K
80299 <1% 2,702 $11K
86644 <1% 3,674 $11K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 3,370 $11K
87150 <1% 844 $11K
88342 <1% 245 $11K
87046 <1% 15,988 $11K
82668 <1% 3,260 $11K
85379 <1% 6,367 $11K
80051 <1% 5,932 $11K
86357 <1% 11,301 $11K
86645 <1% 3,126 $10K
83698 <1% 1,618 $10K
36415 Collection of venous blood by venipuncture <1% 977,501 $10K
81479 Unlisted molecular pathology procedure <1% 256 $10K
80175 <1% 3,225 $9K
86777 <1% 2,616 $9K
85041 <1% 17,112 $9K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 495 $9K
83519 <1% 3,555 $9K
83835 <1% 2,630 $9K
87076 <1% 3,728 $8K
99001 <1% 9,827 $8K
85306 <1% 2,217 $8K
84155 <1% 13,764 $8K
87506 <1% 117 $7K
82747 <1% 4,708 $7K
80156 <1% 2,849 $7K
86258 <1% 1,911 $7K
87040 <1% 3,479 $7K
80185 <1% 2,715 $7K
86036 <1% 2,361 $7K
82164 <1% 2,019 $7K
85303 <1% 2,076 $6K
82232 <1% 5,505 $6K
89055 <1% 5,745 $6K
86148 <1% 4,133 $6K
82397 <1% 2,215 $6K
83718 <1% 5,914 $6K
86794 <1% 516 $6K
86707 <1% 6,397 $6K
81015 <1% 8,107 $6K
84482 <1% 1,693 $5K
88304 <1% 253 $5K
82085 <1% 2,917 $5K
81270 <1% 558 $5K
86335 <1% 926 $5K
86308 <1% 4,899 $5K
87563 <1% 1,223 $5K
86617 <1% 1,130 $5K
84132 <1% 12,119 $5K
87101 <1% 3,911 $5K
82104 <1% 1,060 $5K
82653 <1% 1,371 $5K
84378 <1% 1,128 $4K
86774 <1% 1,207 $4K
85597 <1% 1,049 $4K
86778 <1% 1,369 $4K
84295 <1% 8,822 $4K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 68 $4K
80361 <1% 11,379 $4K
87521 Neg quan hep c or qual rna <1% 437 $3K
85598 <1% 676 $3K
85048 <1% 8,080 $3K
80202 <1% 1,740 $3K
85300 <1% 1,393 $3K
84484 <1% 2,134 $3K
87140 <1% 1,376 $3K
85004 <1% 3,059 $3K
86256 <1% 1,344 $3K
82985 <1% 1,317 $3K
84300 <1% 3,621 $3K
82340 <1% 2,350 $3K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,579 $3K
86663 <1% 699 $3K
82955 <1% 1,205 $2K
82166 <1% 660 $2K
85660 <1% 1,489 $2K
85384 <1% 2,091 $2K
80158 <1% 575 $2K
86886 <1% 1,874 $2K
80195 <1% 689 $2K
86648 <1% 630 $2K
86231 <1% 877 $2K
83935 <1% 2,244 $2K
86060 <1% 2,176 $2K
80180 <1% 288 $2K
87634 <1% 119 $2K
84080 <1% 493 $2K
87206 <1% 2,264 $2K
83003 <1% 775 $2K
80183 <1% 548 $2K
86692 <1% 730 $2K
87220 <1% 2,479 $2K
80503 <1% 280 $2K
82787 <1% 598 $2K
81403 <1% 70 $2K
87102 <1% 1,311 $2K
82705 <1% 1,224 $1K
G0475 Hiv antigen/antibody, combination assay, screening <1% 1,966 $1K
87467 <1% 374 $1K
83930 <1% 1,378 $1K
82507 <1% 535 $1K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 1,179 $1K
82435 <1% 4,296 $1K
80162 <1% 976 $1K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 662 $1K
86905 <1% 1,623 $1K
81279 <1% 71 $1K
82139 <1% 151 $1K
84252 <1% 344 $1K
83825 <1% 619 $1K
82175 <1% 428 $1K
87230 <1% 473 $1K
84376 <1% 640 $1K
87272 <1% 530 $963.71
80169 <1% 304 $950.73
81219 <1% 65 $943.37
84255 <1% 164 $911.45
86790 <1% 232 $911.26
87328 <1% 563 $881.36
86671 <1% 671 $872.13
80165 <1% 232 $834.91
81327 <1% 1,079 $812.51
82553 <1% 356 $784.55
83945 <1% 595 $783.94
88312 <1% 26 $765.30
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 735 $752.37
82575 <1% 534 $737.73
80365 <1% 7,109 $734.85
82384 <1% 150 $729.51
80349 <1% 10,121 $725.95
82523 <1% 369 $719.16
83630 <1% 68 $704.05
83986 <1% 1,041 $681.62
87185 <1% 1,711 $648.69
85250 <1% 119 $646.29
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 223 $644.39
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 16 $626.02
86703 <1% 615 $622.13
85049 <1% 984 $616.27
86615 <1% 210 $608.80
86880 <1% 896 $605.97
87341 <1% 340 $596.07
80184 <1% 350 $595.91
87015 <1% 484 $564.79
88341 <1% 13 $560.82
82656 <1% 304 $534.60
36416 <1% 366 $517.60
82552 <1% 453 $489.01
87107 <1% 299 $475.27
81256 <1% 12 $451.52
84238 <1% 114 $444.67
81207 <1% 25 $439.60
82671 <1% 27 $436.92
87912 <1% 61 $423.46
84560 <1% 834 $415.42
87254 <1% 267 $399.91
85651 <1% 820 $390.66
86001 <1% 395 $375.52
86611 <1% 353 $374.14
82681 <1% 159 $353.97
84182 <1% 42 $352.63
87280 <1% 327 $346.53
86316 <1% 94 $343.01
87116 <1% 147 $323.93
81339 <1% 25 $317.06
86606 <1% 90 $316.91
83951 <1% 101 $314.34
86403 <1% 76 $299.86
87106 <1% 293 $298.31
86747 <1% 463 $293.18
84133 <1% 677 $281.37
80321 <1% 3,526 $278.19
82374 <1% 961 $263.92
82679 <1% 27 $252.98
86161 <1% 80 $247.86
83605 <1% 153 $241.14
84105 <1% 513 $238.27
82608 <1% 69 $233.64
81240 <1% 27 $227.26
86037 <1% 110 $195.53
86710 <1% 64 $194.40
80201 <1% 55 $174.29
99199 Unlisted special service, procedure or report <1% 8,850 $151.87
87275 <1% 415 $148.31
87276 <1% 419 $143.05
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 14 $142.63
84145 <1% 12 $135.90
87172 <1% 103 $131.70
84392 <1% 356 $118.92
80346 <1% 5,290 $108.84
80323 <1% 1,491 $106.19
83625 <1% 130 $100.48
82595 <1% 69 $92.31
86340 <1% 67 $89.26
82365 <1% 127 $89.16
87425 <1% 84 $76.19
80355 <1% 2,150 $72.00
85670 <1% 53 $71.26
83527 <1% 43 $68.14
86609 <1% 39 $64.60
82379 <1% 12 $62.62
84143 <1% 63 $62.07
86784 <1% 19 $60.30
82731 <1% 27 $56.19
82308 <1% 77 $53.45
83874 <1% 27 $48.15
80348 <1% 7,260 $29.57
86738 <1% 17 $26.66
82180 <1% 13 $25.31
84206 <1% 12 $19.78
84202 <1% 41 $14.16
85305 <1% 15 $11.69
89051 <1% 17 $9.92
80357 <1% 502 $8.29
87207 <1% 12 $6.03
80335 0% 1,030 $0.00
80320 0% 157 $0.00
80324 0% 3,833 $0.00
99000 0% 12,626 $0.00
80359 0% 839 $0.00
80358 0% 1,628 $0.00
80367 0% 822 $0.00
80353 0% 1,704 $0.00
80374 0% 322 $0.00
80345 0% 1,221 $0.00
80368 0% 880 $0.00
80340 0% 82 $0.00
81374 0% 81 $0.00
86041 0% 24 $0.00
80371 0% 230 $0.00
86684 0% 115 $0.00
80330 0% 82 $0.00
80333 0% 82 $0.00
81255 0% 22 $0.00
82677 0% 12 $0.00
87503 0% 12 $0.00
87807 0% 24 $0.00
99058 0% 80 $0.00
82270 0% 46 $0.00
89320 0% 13 $0.00
81200 0% 22 $0.00
80363 0% 12 $0.00
80329 0% 13 $0.00
80356 0% 1,311 $0.00
80373 0% 5,253 $0.00
0001M 0% 229 $0.00
80362 0% 4,510 $0.00
80360 0% 3,124 $0.00
80372 0% 1,863 $0.00
83992 0% 1,193 $0.00
80366 0% 1,548 $0.00
80326 0% 94 $0.00
80369 0% 1,806 $0.00
80354 0% 1,585 $0.00
80500 0% 193 $0.00
80337 0% 94 $0.00
81260 0% 22 $0.00
81241 0% 57 $0.00
80344 0% 82 $0.00
80370 0% 94 $0.00
80377 0% 94 $0.00
80338 0% 94 $0.00
80364 0% 82 $0.00
80342 0% 12 $0.00
80332 0% 12 $0.00
80339 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.